Table 2.
Reasons | Step 1 (N=24) N (%) | Step 2 (N=12) N (%) |
---|---|---|
Treatment completed | - | 1(8.0%) |
Disease progression | 13 (54 %) | 7 (54%) |
Adverse events | 5 (21 %) | 0(0.0%) |
Death on study a | 1 (4.0%) | 0(0.0%) |
Withdrawal or refusal | 4 (17 %) | 2 (17%) |
Alternative therapy | 0(0.0%) | 1(8.0%) |
Other | 1 (4.0%)b | 1(8.0%)c |
Death was considered likely related to progression and unrelated to treatment
Progression could not be confirmed because cytology of new effusion was not obtained
Symptomatic deterioration with worsening performance status.